公开(公告)号：US11654104B2

公开(公告)日：2023-05-23

申请号：US16709833

申请日：2019-12-10

Applicant: Evive Biotechnology (Shanghai) Ltd

Inventor： Xiaoqiang Yan ,  Cheng Huang ,  Dongdong Wu ,  Kaiyang Tang ,  Yuliang Huang

IPC: A61K38/20 ,  C07K14/54 ,  A61K9/00

CPC classification number: A61K9/0019 ,  A61K38/20 ,  C07K14/54

Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 μg/kg to about 200 μg/kg (such as about 10 μg/kg to about 45 μg/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.

公开(公告)号：US11564973B2

公开(公告)日：2023-01-31

申请号：US16724491

申请日：2019-12-23

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.

Inventor： Marcel Van Den Brink ,  Alan Hanash ,  Caroline Lindemans ,  Tom Tang

IPC: A61K38/20 ,  C07K14/54 ,  C07K16/46 ,  C07K16/42

Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.

公开(公告)号：US11510966B2

公开(公告)日：2022-11-29

申请号：US16093583

申请日：2017-04-14

Applicant: Evive Biotechnology (Shanghai) Ltd ,  UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Jay Kennedy Kolls ,  Misty Lynn Good ,  Xiaoqiang Yan

IPC: A61K38/20 ,  A61P1/00 ,  A61K9/00

Abstract: The present invention relates to methods of preventing and/or treating necrotizing enterocolitis or other intestinal inflammations using an IL-22, a dimer or a multimer thereof.

公开(公告)号：US20230301901A1

公开(公告)日：2023-09-28

申请号：US18299343

申请日：2023-04-12

Applicant: Evive Biotechnology (Shanghai) Ltd

Inventor： Xiaoqiang YAN ,  Cheng HUANG ,  Dongdong WU ,  Kaiyang TANG ,  Yuliang HUANG

IPC: A61K9/00 ,  A61K38/20 ,  C07K14/54

CPC classification number: A61K9/0019 ,  A61K38/20 ,  C07K14/54

Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 µg/kg about 200 µg/kg (such as about 10 µg/kg to about 45 µg/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.

公开(公告)号：US20230079150A1

公开(公告)日：2023-03-16

申请号：US17799627

申请日：2021-02-10

Applicant: Evive Biotechnology (Shanghai) Ltd

Inventor： Zheng YANG ,  Zhihua HUANG

IPC: A61K38/20 ,  A61K31/7064 ,  A61K31/427 ,  A61K38/21 ,  A61P11/00

Abstract: Provided is use of IL-22 dimer in prevention or treatment of virus-induced organ injury or failure, such as lung injury or failure, sepsis, septic shock, or multiple organ dysfunction syndrome (MODS) associated with virus infection.

公开(公告)号：US20230293635A1

公开(公告)日：2023-09-21

申请号：US18156016

申请日：2023-01-18

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EVIVE BIOTECHNOLOGY (SHANGHAI) LTD

Inventor： Marcel VAN DEN BRINK ,  Alan HANASH ,  Caroline LINDEMANS ,  Tom TANG

IPC: A61K38/20 ,  C07K14/54

CPC classification number: A61K38/20 ,  C07K14/54 ,  C07K16/42

Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.

公开(公告)号：US20230084309A1

公开(公告)日：2023-03-16

申请号：US17800827

申请日：2021-02-19

Applicant: Evive Biotechnology (Shanghai) Ltd

Inventor： William DALEY ,  Xiaoqiang YAN

IPC: A61K47/64 ,  A61K31/573 ,  A61P37/06

Abstract: Provided are methods for treating graft versus host disease (GvHD) by administering a composition an agent comprising an IL-22 (such as an IL-22 dimer), and optionally an immunosuppressive therapy. The treatment can be administered for multiple cycles which are separated by a rest period and/or individuals who have a specific Ann Arbor score or a characterized gut microbiota profile. Also provided are methods of identifying or selecting individuals suitable for such treatments.